Trimethylammonium

Trimethylammonium

SCHEMBL4940092

CCN(C(C)C)C(C)C.CN(C)C

nearest known ligand 0.38

Full drug profile on Sugi Atlas →

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1746 0.93
SCHEMBL5544690 0.93 MEN1 (0.42) MEN1KMT2A
SCHEMBL7097725 0.93
N,N-Dimethylethanaminium SCHEMBL854736 0.90 MEN1 (0.36) MEN1KMT2A
SCHEMBL2232066 0.89 MEN1 (0.40) MEN1KMT2A
SCHEMBL3210291 0.89 MEN1 (0.40) MEN1KMT2A
Fluoride SCHEMBL73855 0.89 MEN1 (0.40) MEN1KMT2A
SCHEMBL319537 0.89 MEN1 (0.40) MEN1KMT2A
Hydrochloric Acid SCHEMBL22577541 0.89 MEN1 (0.40) MEN1KMT2A
Ammonia Solution, Strong SCHEMBL1997314 0.89 MEN1 (0.40) MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230390322-A1 HIGH CONCENTRATION METHYLCOBALAMIN OR COMBINATION OF METHYL- AND HYDROXY-COBALAMIN FOR THE TREATMENT OF COBALAMIN C DEFICIENCY DISORDERS THE U.S.A., AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2023-12-07 US disclosed
WO-2022081601-A1 HIGH CONCENTRATION METHYLCOBALAMIN OR COMBINATION OF METHYL- AND HYDROXY-COBALAMIN FOR THE TREATMENT OF COBALAMIN C DEFICIENCY DISORDERS THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2022-04-21 WO disclosed
WO-2018046684-A1 PROCESS FOR THE PREPARATION OF SUBSTITUTED 5-{[2-(ALKOXYMETHYL)-3,3,3-TRIFLUORO-2-HYDROXY-1-PHENYLPROPYL]AMINO}QUINOLIN-2(1H)-ONES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-03-15 WO disclosed
CN-102475891-A PH-responsive polyethylene glycol-anticarcinogen conjugate, and synthetic method and application thereof CHINESE ACAD INST CHEMISTRY 2012-05-30 CN disclosed
US-20080039422-A1 Vitamin B12-Containing Compositions and Methods of Use TRANSITION THERAPEUTICS INC. (CA) 2008-02-14 US disclosed
WO-2003045969-A1 COUPLING REAGENT FOR H-PHOSPHONATE CHEMISTRY AVECIA BIOTECHNOLOGY INC. (US) 2003-06-05 WO disclosed
EP-0624163-B1 CYCLIC CALCITONIN DERIVATIVES AND METHOD FOR THEIR PRODUCTION SMITHKLINE BEECHAM FARMA (IT) 1998-03-25 EP disclosed
EP-0624163-A1 CYCLIC CALCITONIN DERIVATIVES AND METHOD FOR THEIR PRODUCTION Smithkline Beecham Farmaceutici S.p.A. (IT) 1994-11-17 EP disclosed
WO-1993015106-A1 CYCLIC CALCITONINE DERIVATIVES AND METHOD FOR THEIR PRODUCTION SMITHKLINE BEECHAM FARMACEUTICI S.P.A. (IT) 1993-08-05 WO disclosed